{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Foreign Desk", "lead_paragraph": "The Food and Drug Administration has approved the first generic triple-therapy AIDS cocktail, opening the way for American taxpayer dollars to be used to buy cheaper medicines for use in poor countries. Assuming the drugs made by the approved company, Aspen Pharmacare of South Africa, are priced at a third to a half of brand-name ones, charities and poor nations getting Bush administration money will be able to treat two or three times as many patients.", "headline": {"main": "A Path to Cheaper AIDS Drugs for Poor Nations"}, "abstract": "FDA approves first generic triple-therapy AIDS drug cocktail, opening way for US taxpayer dollars to be used to buy cheaper medicines in poor countries; Aspen Pharmacare of South Africa has not announced price, but same regimen from Indian makers costs $240-360 per patient per year, compared with about $660 for brand-name medicines (S)", "print_page": "9", "word_count": 651, "_id": "4fd241538eb7c8105d7d9ee8", "snippet": "The F.D.A. has opened the way for U.S. taxpayer dollars to be used to buy cheaper AIDS medicines for use in poor countries.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/01/26/health/26aids.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "ASPEN PHARMACARE"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "THIRD WORLD AND DEVELOPING COUNTRIES"}], "byline": {"person": [{"qualifier": "Jr", "firstname": "Donald", "middlename": "G.", "lastname": "McNEIL", "rank": 1, "role": "reported", "organization": ""}], "original": "By DONALD G. McNEIL Jr"}, "document_type": "article", "pub_date": "2005-01-26T00:00:00Z", "section_name": "World; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Like many prominent researchers at the nation's major medical centers, Eric J. Topol, the chief academic officer of the Cleveland Clinic Foundation, has over the years had consulting and financial ties with numerous drug and medical device companies. Dr. Topol, an outspoken cardiologist who frequently opines on the medical issues of the day, has done work for drug companies like Eli Lilly, the Medicines Company and a partnership of Bristol-Myers Squibb and Sanofi-Aventis.", "headline": {"main": "Patient Care vs. Corporate Connections; Cleveland Clinic Wants to Change but Won't Cut Ties to Industry"}, "abstract": "Cleveland Clinic Foundation's chief academic officer Eric J Topol has come under scrutiny for potential conflicts of interest with pharmaceutical companies; Topol has dones work for drug companies like Eli Lilly, Medicines Co and partnership with Bristol-Myers Squibb and Sanofi-Aventis; report in December by Fortune magazine said that Topol, leading critic of drug Vioxx, was paid consultant to hedge fund that had made money betting that shares of Merck, Vioxx's maker, would fall; Topol severed his ties with that firm; said he had no knowledge of firm's investment position; Cleveland Clinic says it is overhauling its ethics policies, and will present them to board for approval, perhaps within weeks; few academic centers go as far as preventing researchers from studying drug or device from company in which they have any financial interest; Cleveland Clinic is trying to avoid outright bans by asking researchers to disclose their ties and trying to minimize effect of conflicts; Delos M Cosgrove, who took over as clinic's chief executive, says he does not believe that across-the-board restrictions are desirable; graph; photos (M)", "print_page": "1", "word_count": 1863, "_id": "4fd254ea8eb7c8105d7fd1d3", "snippet": "As drug makers are increasingly scrutinized for their relationships to researchers, the Cleveland Clinic Foundation's chief academic officer is finding himself under the spotlight.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/01/25/business/25cleveland.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "TOPOL, ERIC"}, {"name": "persons", "value": "COSGROVE, DELOS M"}, {"name": "organizations", "value": "MEDICINES CO"}, {"name": "organizations", "value": "SANOFI-AVENTIS"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "LILLY, ELI, & CO"}, {"name": "organizations", "value": "BRISTOL-MYERS SQUIBB CO"}, {"name": "organizations", "value": "CLEVELAND CLINIC FOUNDATION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Reed", "rank": 1, "lastname": "ABELSON"}, {"organization": "", "role": "reported", "firstname": "Andrew", "rank": 2, "lastname": "POLLACK"}], "original": "By REED ABELSON and ANDREW POLLACK; Reed Abelson reported from Cleveland for this article and Andrew Pollack from Los Angeles"}, "document_type": "article", "pub_date": "2005-01-25T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "As a psychopharmacologist, I know that every patient responds slightly differently to medication. But it wasn't until I met Susan that I understood just how differently. She'd come to see me because she was depressed, and I'd successfully treated her with a course of Zoloft, a popular antidepressant. But as often happens, Susan's desire for sex had vanished along with her depressed mood.", "headline": {"main": "Sometimes, a Pill Can Hold Surprises for Patient and Doctor Alike", "kicker": "CASES"}, "abstract": "Dr Richard A Friedman Cases column discusses patient suffering from depression and concerns about diminished sexual interest while on antidepressant medication; treatment change to Wellbutrin, which allowed patient to recover sex drive, described; research estimates that 40 to 50 percent of all patients taking selective serotonin reuptake inhibitors suffer sexual side effects; drawing (M)", "print_page": "5", "word_count": 723, "_id": "4fd2809e8eb7c8105d84c432", "snippet": "One doctor discusses an antidepressant's surprising side effect for a female patient.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/01/25/health/25case.html", "multimedia": [{"url": "images/2005/01/24/science/25case.75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2005/01/24/science/25case.75.jpg"}, "type": "image", "height": 75}, {"subtype": "tiny_thumb", "legacy": {"tinythumbwidth": 55, "tinythumbheight": 55, "hastinythumb": "Y"}, "type": "image", "width": 55, "height": 55}], "subsection_name": null, "keywords": [{"name": "subject", "value": "SEX"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}, {"name": "subject", "value": "SEROTONIN (CHEMICAL)"}, {"name": "subject", "value": "WELLBUTRIN (DRUG)"}], "byline": {"person": [{"qualifier": "M.D", "firstname": "Richard", "middlename": "A.", "lastname": "FRIEDMAN", "rank": 1, "role": "reported", "organization": ""}], "original": "By RICHARD A. FRIEDMAN, M.D"}, "document_type": "article", "pub_date": "2005-01-25T00:00:00Z", "section_name": "Health"}], "meta": {"hits": 3, "offset": 0, "time": 31}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}